Discontinuation and nonpublication analysis of chronic pain randomized controlled trials

被引:4
|
作者
Jacobsen, Samuel M. [1 ,2 ]
Moore, Ty [1 ]
Douglas, Alexander [1 ]
Lester, Drew [1 ]
Johnson, Austin L. [1 ]
Vassar, Matt [1 ]
机构
[1] Oklahoma State Univ Ctr Hlth Sci, Off Med Student Res, Tulsa, OK USA
[2] Oklahoma State Univ Ctr Hlth Sci, Off Med Student Res, 1111 W 17th St, Tulsa, OK 74107 USA
关键词
Chronic pain; Research waste; Discontinuation; Nonpublication; CLINICAL-TRIALS; OSTEOARTHRITIS PAIN; PUBLICATION; EFFICACY; MULTICENTER; PREVALENCE; RELEASE; SAFETY;
D O I
10.1097/PR9.0000000000001069
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Introduction: The primary objective of this cross-sectional analysis is to evaluate rates of discontinuation and nonpublication of Randomized controlled trials (RCTs) of therapeutic interventions to treat chronic pain. Methods: Using ClinicalTrials.gov, a sample was obtained which included clinical trials pertaining to chronic pain. Trials were analyzed for publication status and completion status of each trial. If information was unavailable on the trial registry database, or could not be allocated through a systematic search, the corresponding trialist was contacted and data points were gathered.Results: In our final analysis of the 408 RCTs, we found that 281 (68.9%) were published in a peer-reviewed journal and 127 (31.1%) were unpublished trials. Of 112 discontinued trials, 59 (52.7%) reached publication. In addition, 221 of 296 completed trials (74.7%) were published, and 75 (25.3%) remained unpublished after trial completion. The most common listed reason for trial discontinuation was administrative recommendations (41 of 71 trials [57.7%]), while not receiving an email reply to our standardized email from the corresponding trialist was the most common result for trial nonpublication (49 of 88 trials [55.7%]). Clinical trials funded by nonindustry sponsors were more likely to reach publication than industry-funded clinical trials (unadjusted odds ratio 1.86 [95% CI, 1.18-2.95]; adjusted odds ratio 3.01 [95% CI, 1.76-5.14]).Conclusion: The rate of discontinuation of RCTs involving patients with chronic pain is concerning. Chronic pain affects many patients; thus, the importance of having quality data from clinical trials cannot be overstated. Our study indicates that chronic pain RCTs are frequently discontinued and their findings often go unpublished - all of which could provide crucial information to providers and patients regarding the treatment of chronic pain. We offer suggestions to enhance chronic pain RCT completion, thereby reducing the waste of resources in chronic pain research.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Analysis of the discontinuation and nonpublication of neurooncological randomized clinical trials
    Butler, Molly
    Mehra, Mehul
    Chandasir, Abdullah
    Kaoutzani, Lydia
    Vale, Fernando L.
    [J]. NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
  • [2] Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated metaresearch analysis
    Speich, Benjamin
    Gryaznov, Dmitry
    Busse, Jason W.
    Gloy, Viktoria L.
    Lohner, Szimonetta
    Klatte, Katharina
    Heravi, Ala Taji
    Ghosh, Nilabh
    Lee, Hopin
    Mansouri, Anita
    Marian, Ioana R.
    Saccilotto, Ramon
    Nury, Edris
    Kasenda, Benjamin
    Ojeda-Ruiz, Elena
    Schandelmaier, Stefan
    Tomonaga, Yuki
    Amstutz, Alain
    Pauli-Magnus, Christiane
    Bischoff, Karin
    Wollmann, Katharina
    Rehner, Laura
    Meerpohl, Joerg J.
    Nordmann, Alain
    Wong, Jacqueline
    Chow, Ngai
    Hong, Patrick Jiho
    Mc Cord-De Iaco, Kimberly
    Sricharoenchai, Sirintip
    Agarwal, Arnav
    Schwenkglenks, Matthias
    Hemkens, Lars G.
    von Elm, Erik
    Copsey, Bethan
    Griessbach, Alexandra N.
    Schoenenberger, Christof
    Mertz, Dominik
    Bluemle, Anette
    von Niederhaeusern, Belinda
    Hopewell, Sally
    Odutayo, Ayodele
    Briel, Matthias
    [J]. PLOS MEDICINE, 2022, 19 (04)
  • [3] Nonpublication and discontinuation of randomised controlled trials in newborns
    Ruegger, Christoph M.
    Dawson, Jennifer A.
    Donath, Susan M.
    Owen, Louise S.
    Davis, Peter G.
    [J]. ACTA PAEDIATRICA, 2017, 106 (12) : 1940 - 1944
  • [4] Discontinuation and Nonpublication of Randomized Clinical Trials Conducted in Children
    Pica, Natalie
    Bourgeois, Florence
    [J]. PEDIATRICS, 2016, 138 (03)
  • [5] Rates of Discontinuation and Nonpublication of Head and Neck Cancer Randomized Clinical Trials
    Johnson, Austin L.
    Fladie, Ian
    Anderson, J. Michael
    Lewis, David M.
    Mons, Bradley R.
    Vassar, Matt
    [J]. JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2020, 146 (02) : 176 - 182
  • [6] Characterization of discontinuation and nonpublication of phase III randomized clinical trials of psoriasis
    Lam, Megan
    Monaghan, Caitlin
    Chan, An-Wen
    Drucker, Aaron M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (01) : 127 - 129
  • [7] A PRELIMINARY ANALYSIS OF THE RATES OF DISCONTINUATION AND NONPUBLICATION IN UROLOGIC ONCOLOGY TRIALS
    Johnson, Bradley
    Pena, Andriana
    Smith, Caleb
    Fladie, Ian
    Vassar, Matt
    [J]. JOURNAL OF UROLOGY, 2021, 206 : E995 - E995
  • [8] Discontinuation and nonpublication of clinical trials in orthopaedic oncology
    Gurbinder Singh
    Aboubacar Wague
    Ayush Arora
    Varun Rao
    Derek Ward
    Jeffrey Barry
    [J]. Journal of Orthopaedic Surgery and Research, 19
  • [9] Discontinuation and nonpublication of pediatric otolaryngology clinical trials
    Johnson, Austin L.
    Torgerson, Trevor
    Adewumi, Mopileola Tomi
    Kee, Micah
    Farahani, Clay
    Wehrmann, Daniel J.
    Francis, Carrie L.
    Vassar, Matt
    [J]. INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2021, 151
  • [10] Discontinuation and nonpublication of nasopharyngeal carcinoma clinical trials
    Huang, Huageng
    Chen, Zegeng
    Zhu, Manyi
    Deng, Xinyi
    Yu, Le
    Weng, Huawei
    Yao, Yuyi
    Hong, Huangming
    Fang, Xiaojie
    Wang, Zhao
    Tian, Ying
    Huang, He
    Lin, Tongyu
    [J]. ORAL ONCOLOGY, 2024, 148